Trevi Therapeutics, Inc. TRVI Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s accrued liabilities?
- Trevi Therapeutics, Inc. (TRVI) reported accrued liabilities of -$1.08M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s accrued liabilities changed year-over-year?
- Trevi Therapeutics, Inc.'s accrued liabilities increased by 28.4% year-over-year, from -$1.5M to -$1.08M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s accrued liabilities?
- Over 2 years (2021 to 2023), Trevi Therapeutics, Inc.'s accrued liabilities has grown at a -60.7% compound annual growth rate (CAGR), from $336K to $52K.
- What does accrued liabilities mean?
- Represents the net change in obligations for expenses incurred but not yet invoiced or paid by the end of the reporting period. This metric reflects the company's short-term operational liabilities and provides insight into the timing of cash outflows for accrued services or goods.